KCNT1-related epilepsy: An international multicenter cohort of 27 pediatric cases

Felippe Borlot1, Ahmed Abushama1, Nadine Morrison-Levy1,2

  • 1Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.

Epilepsia
|March 14, 2020
PubMed

Insights

This study highlights KCNT1-related epilepsy, often presenting as epilepsy of infancy with migrating focal seizures (EIMFS) and refractory tonic seizures. Cannabidiol, diet, and quinidine show promise for seizure reduction in these patients.

Area of Science:

  • Genetics
  • Neurology
  • Pediatrics

Background:

  • KCNT1 gene variants are associated with severe early-onset epilepsy syndromes.
  • Understanding genotype-phenotype correlations is crucial for managing KCNT1-related epilepsy.
  • A multiethnic cohort evaluation provides insights into phenotypic variability.

Purpose of the Study:

  • To evaluate phenotypic aspects of KCNT1-related epilepsy in a multiethnic cohort.
  • To explore genotype-phenotype correlations for common KCNT1 variants.
  • To identify potential therapeutic strategies for seizure control.

Main Methods:

  • Cross-sectional analysis of children with pathogenic/likely pathogenic KCNT1 variants.
  • Comparison of children with common recurrent variants versus the rest of the cohort.
  • Phenotypic data collection including seizure types, developmental trajectory, and treatment response.

Main Results:

  • Twenty-seven children were included, with seizure onset typically in early infancy.
  • Epilepsy of infancy with migrating focal seizures (EIMFS) and focal tonic seizures were prevalent.
  • Cannabidiol, diet therapy, and quinidine demonstrated potential for seizure reduction, though evidence is limited.

Conclusions:

  • KCNT1-related epilepsy is a highly pleiotropic condition with common features like EIMFS and refractory tonic seizures.
  • Cannabidiol, diet therapies, and quinidine represent promising avenues for seizure management.
  • Further evidence-based research is needed to establish optimal treatment protocols.
Abstract